Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study
ConclusionSubsequent treatment with ALN or ZOL but not NT and RIS mitigates BMD loss after Dmab discontinuation. (Source: Osteoporosis International)
Source: Osteoporosis International - January 5, 2023 Category: Orthopaedics Source Type: research
Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF- κB and RhoA/ROCK1/MLCP signaling
Chronic obstructive pulmonary disease (COPD) is a progressive disorder that causes airway obstruction and lung inflammation. The first-line treatment of COPD is the bronchodilators of β2-agonists and antimusca... (Source: Respiratory Research)
Source: Respiratory Research - December 28, 2022 Category: Respiratory Medicine Authors: Di Liu, Wen Xu, Yuan Tang, Jingxue Cao, Ran Chen, Dingwei Wu, Hongpeng Chen, Bo Su and Jinfu Xu Tags: Research Source Type: research
Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF- κB and RhoA/ROCK1/MLCP signaling
CONCLUSIONS: Nebulization of RIS could alleviate airway obstruction and lung inflammation in COPD, providing a novel strategy for treating COPD patients, even those with β2-agonists tolerance.PMID:36575527 | DOI:10.1186/s12931-022-02274-5 (Source: Cell Research)
Source: Cell Research - December 27, 2022 Category: Cytology Authors: Di Liu Wen Xu Yuan Tang Jingxue Cao Ran Chen Dingwei Wu Hongpeng Chen Bo Su Jinfu Xu Source Type: research
Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF- κB and RhoA/ROCK1/MLCP signaling
CONCLUSIONS: Nebulization of RIS could alleviate airway obstruction and lung inflammation in COPD, providing a novel strategy for treating COPD patients, even those with β2-agonists tolerance.PMID:36575527 | DOI:10.1186/s12931-022-02274-5 (Source: Respiratory Care)
Source: Respiratory Care - December 27, 2022 Category: Respiratory Medicine Authors: Di Liu Wen Xu Yuan Tang Jingxue Cao Ran Chen Dingwei Wu Hongpeng Chen Bo Su Jinfu Xu Source Type: research
Etoricoxib as a treatment of choice for patients with SLCO2A1 mutation exhibiting autosomal recessive primary hypertrophic osteoarthropathy: A case report
We reported a 22-year-old Emirati male with autosomal recessive primary hypertrophic osteoarthropathy caused by a possibly pathogenic homozygous non-synonymous variant in the SLCO2A1 gene (NM_005630.3: c.289C>T, p. Arg97Cys) presenting with joint swelling, forehead furrowing, and significant clubbing in all fingers and toes. Currently, no standard treatments are approved for this disease; medical care is palliative and includes non-steroidal anti-inflammatory drugs, corticosteroids, tamoxifen, retinoids, and risedronate. Colchicine may be helpful for the pain due to subperiosteal new bone formation. Our patient was trea...
Source: Frontiers in Genetics - December 13, 2022 Category: Genetics & Stem Cells Source Type: research
Risedronate-loaded aerogel scaffolds for bone regeneration
Drug Deliv. 2023 Dec;30(1):51-63. doi: 10.1080/10717544.2022.2152135.NO ABSTRACTPMID:36474425 | DOI:10.1080/10717544.2022.2152135 (Source: Drug Delivery)
Source: Drug Delivery - December 7, 2022 Category: Drugs & Pharmacology Authors: Nahla El-Wakil Rabab Kamel Azza A Mahmoud Alain Dufresne Ragab E Abouzeid Mahmoud T Abo El-Fadl Amr Maged Source Type: research
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions-Influence of the type of ion and drug on the release profile
J Biomed Mater Res B Appl Biomater. 2022 Nov 30. doi: 10.1002/jbm.b.35209. Online ahead of print.ABSTRACTBisphosphonates are drugs that are used to treat osteoporosis that causes the low mineral density of the bones. These drugs can be delivered in several ways, but each method has disadvantages. Materials with high potential as carriers of these drugs are zeolites with divalent ions. The aim of this study was to investigate the effect of divalent cations (calcium, magnesium, zinc) and drug type (risedronate, zoledronate) on sorption and release of the drug for osteoporosis. It was proved that drug sorption occurs on all z...
Source: Biomed Res - December 1, 2022 Category: Research Authors: Mariusz Sandomierski Marcel Jakubowski Maria Ratajczak Monika Pokora Monika Zieli ńska Adam Voelkel Source Type: research
Release of drugs used in the treatment of osteoporosis from zeolites with divalent ions —Influence of the type of ion and drug on the release profile
AbstractBisphosphonates are drugs that are used to treat osteoporosis that causes the low mineral density of the bones. These drugs can be delivered in several ways, but each method has disadvantages. Materials with high potential as carriers of these drugs are zeolites with divalent ions. The aim of this study was to investigate the effect of divalent cations (calcium, magnesium, zinc) and drug type (risedronate, zoledronate) on sorption and release of the drug for osteoporosis. It was proved that drug sorption occurs on all zeolites presented in this work. Risedronate sorption was highest in zinc zeolite and lowest in ca...
Source: Journal of Biomedical Materials Research Part B: Applied Biomaterials - December 1, 2022 Category: Materials Science Authors: Mariusz Sandomierski,
Marcel Jakubowski,
Maria Ratajczak,
Monika Pokora,
Monika Zieli ńska,
Adam Voelkel Tags: RESEARCH ARTICLE Source Type: research
Identification and in-vitro analysis of potential proteasome inhibitors targeting PSM β5 for multiple myeloma
Biomed Pharmacother. 2022 Nov 15;157:113963. doi: 10.1016/j.biopha.2022.113963. Online ahead of print.ABSTRACTThe proteasome subunit β5 (PSMβ5) is a chief target of proteasome inhibitors (PIs) for treatment of multiple myeloma (MM). The relevance of PSMβ5 mutations and their functional impact on the development of resistance to PIs have been demonstrated recently. Therefore, this present study deals with an in-depth E-pharmacophore based screening and repurposing of FDA-approved drugs that could target PSMβ5 for MM. Our molecular docking-based investigation revealed risedronate and zoledronate as potential alternative ...
Source: Biomed Res - November 18, 2022 Category: Research Authors: Rohitash Yadav Uttam Kumar Nath Ismail Celik Shailendra Handu Neeraj Jain Puneet Dhamija Source Type: research
Identification and in-vitro analysis of potential proteasome inhibitors targeting PSM β5 for multiple myeloma
Biomed Pharmacother. 2022 Nov 15;157:113963. doi: 10.1016/j.biopha.2022.113963. Online ahead of print.ABSTRACTThe proteasome subunit β5 (PSMβ5) is a chief target of proteasome inhibitors (PIs) for treatment of multiple myeloma (MM). The relevance of PSMβ5 mutations and their functional impact on the development of resistance to PIs have been demonstrated recently. Therefore, this present study deals with an in-depth E-pharmacophore based screening and repurposing of FDA-approved drugs that could target PSMβ5 for MM. Our molecular docking-based investigation revealed risedronate and zoledronate as potential alternative ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 18, 2022 Category: Drugs & Pharmacology Authors: Rohitash Yadav Uttam Kumar Nath Ismail Celik Shailendra Handu Neeraj Jain Puneet Dhamija Source Type: research
Chitosan - zeolite scaffold as a potential biomaterial in the controlled release of drugs for osteoporosis
Int J Biol Macromol. 2022 Nov 11:S0141-8130(22)02629-0. doi: 10.1016/j.ijbiomac.2022.11.071. Online ahead of print.ABSTRACTChitosan scaffolds are a potential material in many biomedical applications. A particularly interesting application is their use in bone tissue engineering. Because of their biocompatibility and nontoxicity, they are an ideal material for this application. What is missing from chitosan scaffolds is controlled drug release. They can obtain this property by adding drug carriers. In this work, chitosan‑calcium zeolite scaffolds were prepared and used in the controlled release of the drug for osteoporosi...
Source: International Journal of Biological Macromolecules - November 14, 2022 Category: Biochemistry Authors: Mariusz Sandomierski Katarzyna Adamska Maria Ratajczak Adam Voelkel Source Type: research
Chitosan - zeolite scaffold as a potential biomaterial in the controlled release of drugs for osteoporosis
Int J Biol Macromol. 2022 Nov 11:S0141-8130(22)02629-0. doi: 10.1016/j.ijbiomac.2022.11.071. Online ahead of print.ABSTRACTChitosan scaffolds are a potential material in many biomedical applications. A particularly interesting application is their use in bone tissue engineering. Because of their biocompatibility and nontoxicity, they are an ideal material for this application. What is missing from chitosan scaffolds is controlled drug release. They can obtain this property by adding drug carriers. In this work, chitosan‑calcium zeolite scaffolds were prepared and used in the controlled release of the drug for osteoporosi...
Source: International Journal of Biological Macromolecules - November 14, 2022 Category: Biochemistry Authors: Mariusz Sandomierski Katarzyna Adamska Maria Ratajczak Adam Voelkel Source Type: research
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk-benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outco...
Source: Aging Clinical and Experimental Research - November 4, 2022 Category: Geriatrics Authors: Nicholas Fuggle Nasser Al-Daghri Olivier Bock Jaime Branco Olivier Bruy ère Enrique Casado Etienne Cavalier Bernard Cortet Maarten de Wit Andrea Giusti Philippe Halbout Nicholas C Harvey Micka ël Hiligsmann Jean-Marc Kaufman Andreas Kurth Stefania Maggi Source Type: research
